Marker Therapeutics, Inc.

Daily Archives: Tuesday, January 24, 2017

Exclusive: Interview With TapImmune, Inc. (NASDAQ: TPIV) President And COO, Dr. John Bonfiglio

If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.

Read More

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

TapImmune, Inc. (NASDAQ: TPIV), today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the first safety cohort in its Phase 2 ovarian cancer study.

Read More